Opportunities and challenges for anti-CD47 antibodies in hematological malignancies
CD47 is a cell-surface ligand that is overexpressed in various malignancies and that binds to SIRPα on macrophages to promote tumor cell evasion of phagocytosis. Blocking the CD47-SIRPα axis can increase the phagocytosis of macrophages to exert antitumor effects. CD47-based immunotherapy is a curren...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-02-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1348852/full |
| _version_ | 1827344812826689536 |
|---|---|
| author | Yilan Xu Panruo Jiang Zhenyan Xu Haige Ye |
| author_facet | Yilan Xu Panruo Jiang Zhenyan Xu Haige Ye |
| author_sort | Yilan Xu |
| collection | DOAJ |
| description | CD47 is a cell-surface ligand that is overexpressed in various malignancies and that binds to SIRPα on macrophages to promote tumor cell evasion of phagocytosis. Blocking the CD47-SIRPα axis can increase the phagocytosis of macrophages to exert antitumor effects. CD47-based immunotherapy is a current research focus. The combination of anti-CD47 antibodies with other drugs has shown encouraging response rates in patients with hematological tumors, but side effects also occur. Bispecific antibodies and SIRPα/Fc fusion proteins appear to balance the efficacy and safety of treatment. We review the latest clinical research advances and discuss the opportunities and challenges associated with CD47-based immunotherapy for hematological malignancies. |
| first_indexed | 2024-03-07T22:55:59Z |
| format | Article |
| id | doaj.art-15909978bcbf4c47998000b0ad3a209a |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-03-07T22:55:59Z |
| publishDate | 2024-02-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-15909978bcbf4c47998000b0ad3a209a2024-02-23T04:28:00ZengFrontiers Media S.A.Frontiers in Immunology1664-32242024-02-011510.3389/fimmu.2024.13488521348852Opportunities and challenges for anti-CD47 antibodies in hematological malignanciesYilan Xu0Panruo Jiang1Zhenyan Xu2Haige Ye3Department of Hematology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, ChinaDepartment of Hematology, Dongyang People’s Hospital, Jinhua, ChinaDepartment of Hematology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, ChinaDepartment of Hematology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, ChinaCD47 is a cell-surface ligand that is overexpressed in various malignancies and that binds to SIRPα on macrophages to promote tumor cell evasion of phagocytosis. Blocking the CD47-SIRPα axis can increase the phagocytosis of macrophages to exert antitumor effects. CD47-based immunotherapy is a current research focus. The combination of anti-CD47 antibodies with other drugs has shown encouraging response rates in patients with hematological tumors, but side effects also occur. Bispecific antibodies and SIRPα/Fc fusion proteins appear to balance the efficacy and safety of treatment. We review the latest clinical research advances and discuss the opportunities and challenges associated with CD47-based immunotherapy for hematological malignancies.https://www.frontiersin.org/articles/10.3389/fimmu.2024.1348852/fullcd47anti-CD47 antibodyimmunotherapyhematological malignanciesmagrolimab |
| spellingShingle | Yilan Xu Panruo Jiang Zhenyan Xu Haige Ye Opportunities and challenges for anti-CD47 antibodies in hematological malignancies Frontiers in Immunology cd47 anti-CD47 antibody immunotherapy hematological malignancies magrolimab |
| title | Opportunities and challenges for anti-CD47 antibodies in hematological malignancies |
| title_full | Opportunities and challenges for anti-CD47 antibodies in hematological malignancies |
| title_fullStr | Opportunities and challenges for anti-CD47 antibodies in hematological malignancies |
| title_full_unstemmed | Opportunities and challenges for anti-CD47 antibodies in hematological malignancies |
| title_short | Opportunities and challenges for anti-CD47 antibodies in hematological malignancies |
| title_sort | opportunities and challenges for anti cd47 antibodies in hematological malignancies |
| topic | cd47 anti-CD47 antibody immunotherapy hematological malignancies magrolimab |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1348852/full |
| work_keys_str_mv | AT yilanxu opportunitiesandchallengesforanticd47antibodiesinhematologicalmalignancies AT panruojiang opportunitiesandchallengesforanticd47antibodiesinhematologicalmalignancies AT zhenyanxu opportunitiesandchallengesforanticd47antibodiesinhematologicalmalignancies AT haigeye opportunitiesandchallengesforanticd47antibodiesinhematologicalmalignancies |